Image

Global Acute Myeloid Leukemia Market – Industry Trends and Forecast to 2030

Pharmaceutical

Image

Global Acute Myeloid Leukemia Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Jul 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Acute Myeloid Leukemia Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 2,500.00 USD Million
Diagram Market Size (Forecast Year) USD 5,866.25 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Acute Myeloid Leukemia Market, By Disease Type (Myeloblastic, Promyelocytic, and Myelomonocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) - Industry Trends and Forecast to 2030.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Analysis and Size

Acute Myeloid Leukemia (AML) is a cancer affecting the bone marrow and blood. It is characterized by the rapid growth of abnormal myeloid cells, immature white blood cells that normally develop into various mature blood cells. The treatment of AML typically involves a combination of chemotherapy, targeted therapy, and, in some cases, stem cell transplantation. The specific treatment approach depends on factors such as the patient's age, overall health, and specific genetic characteristics of the leukemia cells.

Data Bridge Market Research analyses that the acute myeloid leukemia market, which was USD 2,500.00 million in 2022, would rocket up to USD 5,866.25 million by 2030 and is expected to undergo a CAGR of 11.3% during the forecast period. This indicates that the market value of myeloblastic dominates the product type segment of the acute myeloid leukemia market owing to the increasing aging population.

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Acute Myeloid Leukemia Market Scope and Segmentation

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Global Acute Myeloid Leukemia Market, By Disease Type (Myeloblastic, Promyelocytic, and Myelomonocytic), Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Homecare, Speciality Centres, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy)

Countries Covered

U.S., Canada, Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East, Brazil, Argentina and rest of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), QIAGEN (U.S.), Abbott (U.S.), Siemens Healthcare GmbH (Germany), Merck KGAA (Germany), Hologic, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), DiaSorin S.p.A. (U.S.), Illumina, Inc. (U.S.), BIOMÉRIEUX (France), Myriad Genetics, Inc. (U.S.), Quest Diagnostics Incorporated. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), BD (U.S.), Exact Sciences Corporation (U.S.), Time Medical Holding (U.S.), PlexBio (Taiwan), MinFound Medical Systems Co., Ltd (China), Medonica Co. LTD (South Korea), CANON MEDICAL SYSTEMS CORPORATION (Japan), FONAR CORP. (U.S.), Sysmex Corporation (Japan), Epigenomics AG (Germany), Sonic Healthcare (Australia), and SternMed GmbH (Germany) among others

Market Opportunities

  • Increasing incidence of AML
  • Improving healthcare infrastructure

Market Definition

Acute myeloid leukemia is a hematological cancer originating from blood-forming cells of the bone marrow. In this type of leukemia, the abnormal white blood cells are formed rapidly and gathered in the bone marrow, and thus, eventually affecting the healthy blood cells. Symptoms include easy bruising, fatigue, breathlessness, and bleeding. Increased risk factors such as carcinogens, bold disorders, and genetics expand the market.

Acute Myeloid Leukemia Market Dynamics

Drivers

  • Increasing incidence of AML

AML is one of the most common types of leukemia, and its incidence is rising globally, including in the Asia-Pacific region. The growing population and aging demographics contribute to the increasing number of AML cases, which can drive market growth.

  • Improving healthcare infrastructure

Many countries in the Asia-Pacific region are investing in their healthcare infrastructure, including cancer treatment facilities and diagnostic capabilities. Expanding and improving healthcare infrastructure can lead to earlier detection and better management of AML, driving market growth.

  • Rising awareness and education

Efforts to raise awareness about AML, its symptoms, and available treatment options can contribute to early diagnosis and prompt intervention. Increased education among healthcare professionals and the general population can drive market growth by encouraging timely treatment initiation.

  • Advancements in treatment options

Research and development efforts are continually improving the understanding of AML and leading to the development of new treatment options. The availability of innovative therapies, such as targeted therapies and immunotherapies, can positively impact the AML market by providing more effective and personalized treatment options.

Opportunities

  • Government initiatives and funding

Government support, funding, and regulatory initiatives aimed at improving cancer care can significantly impact the AML market. Policies promoting early detection, access to treatment, and affordable healthcare can drive market growth.

  • Collaboration and partnerships

Collaboration among pharmaceutical companies, research institutions, and healthcare providers can foster innovation and accelerate the development of new therapies. Collaborative efforts to conduct clinical trials, share data, and exchange knowledge can contribute to advancements in AML treatment and drive market growth.

Restraints/Challenges

  • Lack of awareness and education

Despite efforts to raise awareness about AML, there may still be gaps in knowledge and understanding among healthcare professionals, patients, and the general population. Limited awareness can result in delayed diagnosis, inadequate treatment decisions, and suboptimal patient outcomes.

  • Resistance to conventional therapies

AML is known for its heterogeneity and the development of drug resistance over time. Some patients may not respond adequately to conventional chemotherapy regimens, leading to limited treatment options and poorer prognoses.

This acute myeloid leukemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute myeloid leukemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System. This next-generation digital PCR system helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases
  • In May 2022, Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company’s growing oncology portfolio. This results in increasing liquid biopsy space for precise tumor tests.

Global Acute Myeloid Leukemia Market Scope

The acute myeloid leukemia market is segmented on the basis of disease type, treatment type, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

  • Myeloblastic
  • Promyelocytic
  • Myelomonocytic

Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Hormone Therapy
  • Others

Route of Administration

  • Oral
  • Parentral
  • Others

End User

  • Hospitals
  • Homecare
  • Speciality Centres
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Acute Myeloid Leukemia Market Regional Analysis/Insights

The acute myeloid leukemia market is analysed and market size insights and trends are provided by country, disease type, treatment type, route of administration, end users, and distribution channel as referenced above.

The countries covered in the acute myeloid leukemia market report are U.S., Canada, Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, rest of Middle East, Brazil, Argentina and rest of South America

North America is expected to dominate the market because of the increasing prevalence of acute myeloid leukemia, growing investment in healthcare infrastructure is also boosting the growth of the market.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The acute myeloid leukemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for acute myeloid leukemia market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the acute myeloid leukemia market. The data is available for historic period 2010-2020.

Competitive Landscape and Acute Myeloid Leukemia Market Share Analysis

The acute myeloid leukemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute myeloid leukemia market.

Some of the major players operating in the acute myeloid leukemia market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Thermo Fisher Scientific, Inc. (U.S.)
  • QIAGEN (U.S.)
  • Abbott (U.S.)
  • Siemens Healthcare GmbH (Germany)
  • Merck KGAA (Germany)
  • Hologic, Inc. (U.S.)
  • Agilent Technologies, Inc. (U.S.)
  • DiaSorin S.p.A. (U.S.)
  • Illumina, Inc. (U.S.)
  • BIOMÉRIEUX (France)
  • Myriad Genetics, Inc. (U.S.)
  • Quest Diagnostics Incorporated. (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Koninklijke Philips N.V. (Netherlands)
  • BD (U.S.)
  • Exact Sciences Corporation (U.S.)
  • Time Medical Holding (U.S.)
  • PlexBio (Taiwan)
  • MinFound Medical Systems Co., Ltd (China)
  • Medonica Co. LTD (South Korea)
  • CANON MEDICAL SYSTEMS CORPORATION (Japan)
  • FONAR CORP. (U.S.)
  • Sysmex Corporation (Japan)
  • Epigenomics AG (Germany)
  • Sonic Healthcare (Australia)
  • SternMed GmbH (Germany)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The Acute Myeloid Leukemia Market will be worth USD 5,866.25 million by 2030.
The Acute Myeloid Leukemia Market Growth Rate is 11.3% during the forecast period.
The Increasing incidence of AML, Improving healthcare infrastructure, and Rising awareness and education are the Growth drivers of the Acute Myeloid Leukemia Market.
The disease type, treatment type, route of administration, end users, and distribution channel are the factors on which the Acute Myeloid Leukemia Market research is based.
The F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System and Myriad Genetics, Inc. announced the expansion of its strategic partnership with Intermountain Precision Genomics, a service of Intermountain Healthcare, to add a new liquid biopsy therapy selection test to the company’s growing oncology portfolio are the latest developments in the Acute Myeloid Leukemia Market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials